Royce & Associates LP Boosts Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

Royce & Associates LP increased its holdings in MaxCyte, Inc. (NASDAQ:MXCT) by 146.9% during the fourth quarter, Holdings Channel reports. The firm owned 799,873 shares of the company’s stock after acquiring an additional 475,949 shares during the quarter. Royce & Associates LP’s holdings in MaxCyte were worth $3,327,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in MXCT. Intech Investment Management LLC purchased a new position in MaxCyte in the 3rd quarter worth approximately $51,000. Mudita Advisors LLP lifted its holdings in MaxCyte by 5.6% in the 3rd quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock worth $12,267,000 after purchasing an additional 167,101 shares in the last quarter. Verition Fund Management LLC lifted its holdings in MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after purchasing an additional 6,045 shares in the last quarter. ArrowMark Colorado Holdings LLC lifted its holdings in MaxCyte by 13.8% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock worth $5,426,000 after purchasing an additional 169,250 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC raised its holdings in shares of MaxCyte by 0.7% during the 3rd quarter. Chevy Chase Trust Holdings LLC now owns 1,332,048 shares of the company’s stock worth $5,182,000 after acquiring an additional 9,488 shares in the last quarter. 68.81% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MXCT has been the topic of several recent research reports. Stifel Nicolaus decreased their price objective on MaxCyte from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, March 12th. BTIG Research set a $6.00 price objective on MaxCyte and gave the stock a “buy” rating in a report on Wednesday, March 12th.

MaxCyte Price Performance

Shares of MXCT opened at $3.27 on Thursday. The stock has a market capitalization of $346.71 million, a price-to-earnings ratio of -9.62 and a beta of 1.35. The business’s 50 day simple moving average is $4.10 and its 200-day simple moving average is $3.95. MaxCyte, Inc. has a 1 year low of $2.76 and a 1 year high of $5.26.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.